A Study to Compare Tablets and Capsules of Orforglipron (LY3502970) in Healthy Participants Who Are Obese or Overweight

Prior treatment

• Have undergone bariatric surgery (for example: Lap-Band, Gastric Bypass)

Other illness

• Have a history of current cardiovascular, respiratory, hepatic, renal, gastrointestinal, endocrine, hematological, or neurological disorders or other significant active, uncontrolled medical conditions.
• Have significant history of or currently have major depressive disorder or psychiatric disorder within the last 2 years.
• Obesity induced by other endocrine disorders, such as Cushing's syndrome or Prader-Willi syndrome.
• Have a known self or family history (first-degree relative) of multiple endocrine neoplasia type 2A or type 2B, thyroid C-cell hyperplasia, or any form of thyroid cancer.
• Have history of pancreatitis.

Lab values

• Have hemoglobin A1c (HbA1c) level of 6.5 percent (%) or greater.

Other

• Have known clinically significant gastric emptying abnormality.
• Have an abnormal 12-lead electrocardiogram (ECG) at screening.
• Judged by the study investigator to be at serious suicidal risk and have answered "Yes" to either question 4 or 5 on the Columbia-Suicide Severity Rating Scale \[C-SSRS\]).
• Have difficulty swallowing capsules or tablets.

• Participants who are overtly healthy as determined by medical history and physical examination.
• Have a stable body weight for one month prior to screening (less than or equal to 5 percent body weight gain or loss) and Body Mass Index (BMI) in range of 27 to 40 kilogram per meter square (kg/m²).
• Participants must be reliable and willing to make themselves available for the duration of the study and are willing to follow study procedures.
• Have venous access sufficient to allow for blood sampling.